A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 18 Sep 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 18 Sep 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 10 Jun 2017 Biomarkers information updated